[go: up one dir, main page]

MX2017010338A - Uso de plinabulina en combinación con inhibidores de punto de control inmunitario. - Google Patents

Uso de plinabulina en combinación con inhibidores de punto de control inmunitario.

Info

Publication number
MX2017010338A
MX2017010338A MX2017010338A MX2017010338A MX2017010338A MX 2017010338 A MX2017010338 A MX 2017010338A MX 2017010338 A MX2017010338 A MX 2017010338A MX 2017010338 A MX2017010338 A MX 2017010338A MX 2017010338 A MX2017010338 A MX 2017010338A
Authority
MX
Mexico
Prior art keywords
plinabulin
control point
immune control
combination
point inhibitors
Prior art date
Application number
MX2017010338A
Other languages
English (en)
Other versions
MX394865B (es
Inventor
Huang Lan
Tsi Yie Lee Gloria
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of MX2017010338A publication Critical patent/MX2017010338A/es
Publication of MX394865B publication Critical patent/MX394865B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente composiciones que comprenden Plinabulina y uno o más inhibidores de punto de control inmunitario para tratar cáncer. Algunas modalidades se refieren a métodos para tratar cáncer al co-administrar Plinabulina y uno o más inhibidores de punto de control inmunitario a un sujeto en necesidad del mismo.
MX2017010338A 2015-02-12 2016-02-11 Uso de plinabulina en combinación con inhibidores de punto de control inmunitario MX394865B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115468P 2015-02-12 2015-02-12
US201562255259P 2015-11-13 2015-11-13
PCT/US2016/017602 WO2016130839A1 (en) 2015-02-12 2016-02-11 Use of plinabulin in combination with immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
MX2017010338A true MX2017010338A (es) 2017-12-20
MX394865B MX394865B (es) 2025-03-24

Family

ID=56615698

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010338A MX394865B (es) 2015-02-12 2016-02-11 Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
MX2022007472A MX2022007472A (es) 2015-02-12 2017-08-10 Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022007472A MX2022007472A (es) 2015-02-12 2017-08-10 Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.

Country Status (16)

Country Link
US (1) US20180028531A1 (es)
EP (1) EP3256130A4 (es)
JP (4) JP7243021B2 (es)
KR (2) KR20170117113A (es)
CN (2) CN107427510A (es)
AU (3) AU2016219204B2 (es)
CA (1) CA2975729A1 (es)
CL (1) CL2017002050A1 (es)
HK (1) HK1247816A1 (es)
IL (2) IL286282B2 (es)
MX (2) MX394865B (es)
MY (1) MY193968A (es)
NZ (1) NZ734256A (es)
RU (1) RU2723021C2 (es)
SG (1) SG11201706281YA (es)
WO (1) WO2016130839A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595212A (en) 2009-03-30 2014-02-28 Eisai R&D Man Co Ltd Liposome composition
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
CN107921018A (zh) * 2015-06-11 2018-04-17 生态有限公司 药物组合及其应用
KR102680823B1 (ko) 2015-07-13 2024-07-03 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 조성물
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
ES2952680T3 (es) 2016-04-28 2023-11-03 Eisai R&D Man Co Ltd Eribulina para inhibir el crecimiento tumoral
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN118304304A (zh) 2016-06-06 2024-07-09 大连万春布林医药有限公司 用于减少中性粒细胞减少症的组合物和方法
US11382953B2 (en) 2016-08-26 2022-07-12 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
BR112019007145A2 (pt) * 2016-10-14 2019-07-02 Eisai R&D Man Co Ltd combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (ja) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
AU2018308312B2 (en) 2017-07-26 2021-05-27 Chong Kun Dang Pharmaceutical Corp. Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor
CA3074876A1 (en) * 2017-09-08 2019-03-14 University Health Network Combination therapies for inhibition of polo-like kinase 4
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
US20210161888A1 (en) * 2018-06-01 2021-06-03 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
MX2021001762A (es) * 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
US20210369787A1 (en) * 2018-11-01 2021-12-02 North Carolina State University Adipocyte mediated delivery of anticancer therapeutics
CN110265095A (zh) * 2019-05-22 2019-09-20 首都医科大学附属北京佑安医院 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
KR20230006568A (ko) * 2020-05-04 2023-01-10 비욘드스프링 파마수티컬스, 인코포레이티드. 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
US20240197723A1 (en) * 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
EP4676482A1 (en) * 2023-03-10 2026-01-14 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use
WO2025006507A1 (en) * 2023-06-27 2025-01-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295695T3 (es) * 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
CA2553630A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
AU2006244885B2 (en) * 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
CA2740783A1 (en) * 2008-10-17 2010-04-22 Exelixis, Inc. Sphingosine-1-phosphate receptor antagonists
CA2939165A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
EP2571577A1 (en) * 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
HK1211601A1 (en) * 2012-08-30 2016-05-27 埃姆艮股份有限公司 A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
MX374929B (es) * 2013-02-20 2025-03-06 Novartis Ag RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
WO2014128245A1 (en) * 2013-02-21 2014-08-28 CORAL, Sandra Dna hypomethylating agents for cancer therapy
JP6603209B2 (ja) * 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
JP2016520643A (ja) * 2013-06-03 2016-07-14 ノバルティス アーゲー 抗ｐｄ−ｌ１抗体とｍｅｋ阻害薬および／またはｂｒａｆ阻害薬の組み合わせ物
DK3076972T3 (da) * 2013-10-11 2022-01-03 Beyondspring Inc Cancerbehandling med kombination af plinabulin og taxan
BR112018016054A2 (pt) * 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo

Also Published As

Publication number Publication date
JP2021050247A (ja) 2021-04-01
NZ750444A (en) 2021-03-26
MX394865B (es) 2025-03-24
AU2016219204A1 (en) 2017-08-24
KR20240110996A (ko) 2024-07-16
HK1247816A1 (zh) 2018-10-05
WO2016130839A1 (en) 2016-08-18
MY193968A (en) 2022-11-03
AU2016219204B2 (en) 2021-01-21
AU2024200672A1 (en) 2024-02-22
RU2017127966A (ru) 2019-03-12
SG11201706281YA (en) 2017-09-28
JP2022190005A (ja) 2022-12-22
CN107427510A (zh) 2017-12-01
MX2022007472A (es) 2022-06-29
IL286282B2 (en) 2023-10-01
RU2723021C2 (ru) 2020-06-08
IL253784A0 (en) 2017-09-28
AU2021202416A1 (en) 2021-05-20
JP7243021B2 (ja) 2023-03-22
JP7157181B2 (ja) 2022-10-19
NZ734256A (en) 2019-02-22
IL253784B (en) 2021-09-30
KR20170117113A (ko) 2017-10-20
AU2021202416B2 (en) 2024-02-15
BR112017016902A2 (pt) 2018-03-27
IL286282A (en) 2021-10-31
US20180028531A1 (en) 2018-02-01
EP3256130A4 (en) 2018-08-01
CN117100753A (zh) 2023-11-24
CA2975729A1 (en) 2016-08-18
IL286282B1 (en) 2023-06-01
JP2024174070A (ja) 2024-12-13
JP2018508572A (ja) 2018-03-29
RU2017127966A3 (es) 2019-06-20
EP3256130A1 (en) 2017-12-20
CL2017002050A1 (es) 2018-04-13
JP7564172B2 (ja) 2024-10-08

Similar Documents

Publication Publication Date Title
MX2017010338A (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2022010805A (es) Metodo para reducir la neutropenia.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX389707B (es) Neurotoxinas quimericas.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
HUE053763T2 (hu) Immunellenõrzésipont-gátlók véreredetû rákok kezelésében történõ alkalmazásra
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CO2018009096A2 (es) Composiciones que contienen tucaresol o sus análogos
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2017005555A (es) Inhibidores del bromodominio.
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
MX2017012553A (es) Compuestos espirociclicos.
IL271328A (en) Compositions and methods for enhancing cancer chemotherapy
UY36286A (es) Tratamientos médicos basados en anamorelina